gliclazide has been researched along with Obesity in 21 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gliclazide has been suspected to be associated with a lower obesity-related cancer risk; however, current evidence is limited by important methodologic shortcomings." | 7.96 | Is Gliclazide Associated with a Lower Obesity-Related Cancer Risk Compared to Other Sulfonylureas? A Long-term Prospective Cohort Study. ( de Bock, GH; Du, J; Groenier, KH; Kleefstra, N; Landman, GWD; Schrijnders, D, 2020) |
| "Gliclazide has been suspected to be associated with a lower obesity-related cancer risk; however, current evidence is limited by important methodologic shortcomings." | 3.96 | Is Gliclazide Associated with a Lower Obesity-Related Cancer Risk Compared to Other Sulfonylureas? A Long-term Prospective Cohort Study. ( de Bock, GH; Du, J; Groenier, KH; Kleefstra, N; Landman, GWD; Schrijnders, D, 2020) |
| "The clinical efficacy of gliclazide and its effect on plasma glucose, body weight and serum lipids was assessed in a 3 months open trial of 30 obese, Non-Insulin Dependent diabetes mellitus (NIDDM) patients who failed to respond to diet therapy alone." | 3.68 | Gliclazide in the treatment of obese non-insulin dependent diabetic patients. ( Seshiah, V; Suresh, K; Venkataraman, S, 1993) |
| "Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes." | 2.94 | The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020) |
| "Gliclazide or saline was given q12 h for 48 h to rats received isoprenaline." | 1.38 | Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats. ( Bao, Y; Shuyuan, L; Sun, X; Yang, W; Yerong, Y, 2012) |
| "Insulin resistance is a key feature of type 2 diabetes mellitus." | 1.32 | Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide. ( Antić, S; Bogicević, M; Milojković, M; Mitić-Zlatković, M; Stefanović, V; Stojiljković, S; Vlahović, P, 2003) |
| "The onset of Type 2 diabetes is insidious and is usually recognized only 5-12 years after hyperglycaemia develops." | 1.30 | Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection. ( Muggeo, M, 1998) |
| "Gliclazide was given to group A following CSII and to 5 obese NIDDM patients (group B) in their habitual hyperglycemic state." | 1.28 | Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia. ( Cerasi, E; del Rio, G; Della Casa, L; Glaser, B, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (23.81) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, AK | 1 |
| Woodward, M | 1 |
| Wang, D | 1 |
| Ohkuma, T | 1 |
| Warren, B | 1 |
| Sharrett, AR | 1 |
| Williams, B | 1 |
| Marre, M | 1 |
| Hamet, P | 1 |
| Harrap, S | 1 |
| Mcevoy, JW | 1 |
| Chalmers, J | 1 |
| Selvin, E | 1 |
| Du, J | 1 |
| Kleefstra, N | 1 |
| Schrijnders, D | 1 |
| Groenier, KH | 1 |
| de Bock, GH | 1 |
| Landman, GWD | 1 |
| Anderson, AJ | 1 |
| Andrew, R | 1 |
| Homer, NZ | 1 |
| Jones, GC | 1 |
| Smith, K | 1 |
| Livingstone, DE | 1 |
| Walker, BR | 1 |
| Stimson, RH | 1 |
| Bao, Y | 1 |
| Sun, X | 1 |
| Yerong, Y | 1 |
| Shuyuan, L | 1 |
| Yang, W | 1 |
| Awasthi, R | 1 |
| Kulkarni, GT | 1 |
| Bahadori, B | 1 |
| Trinker, M | 1 |
| Wallner, SJ | 1 |
| Yazdani-Biuki, B | 1 |
| Wascher, TC | 1 |
| Stefanović, V | 2 |
| Antić, S | 2 |
| Mitić-Zlatković, M | 1 |
| Stojiljković, S | 1 |
| Milojković, M | 2 |
| Bogicević, M | 1 |
| Vlahović, P | 2 |
| Lawrence, JM | 1 |
| Reid, J | 1 |
| Taylor, GJ | 1 |
| Stirling, C | 1 |
| Reckless, JP | 1 |
| Inukai, K | 1 |
| Watanabe, M | 1 |
| Nakashima, Y | 1 |
| Sawa, T | 1 |
| Takata, N | 1 |
| Tanaka, M | 1 |
| Kashiwabara, H | 1 |
| Yokota, K | 1 |
| Suzuki, M | 1 |
| Kurihara, S | 1 |
| Awata, T | 1 |
| Katayama, S | 1 |
| Lazarević, G | 1 |
| Wajchenberg, BL | 1 |
| Nery, M | 1 |
| Leme, CE | 1 |
| Silveira, AA | 1 |
| Fioratti, P | 1 |
| Germek, OA | 1 |
| Kumar, S | 1 |
| Keswani, P | 1 |
| Bose, BS | 1 |
| Agrawal, JK | 1 |
| Seshiah, V | 1 |
| Venkataraman, S | 1 |
| Suresh, K | 1 |
| Muggeo, M | 1 |
| Gougeon, R | 1 |
| Styhler, K | 1 |
| Morais, JA | 1 |
| Jones, PJ | 1 |
| Marliss, EB | 1 |
| Crepaldi, G | 1 |
| Fioretto, P | 1 |
| Charbonnel, B | 1 |
| Estivals, JP | 1 |
| Giraudet, MC | 1 |
| Videau, JY | 1 |
| Forette, B | 1 |
| Della Casa, L | 1 |
| del Rio, G | 1 |
| Glaser, B | 1 |
| Cerasi, E | 1 |
| Ward, G | 1 |
| Harrison, LC | 1 |
| Proietto, J | 1 |
| Aitken, P | 1 |
| Nankervis, A | 1 |
1 review available for gliclazide and Obesity
| Article | Year |
|---|---|
Gliclazide modified release: its place in the therapeutic armamentarium.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Secretion; Islets | 2000 |
7 trials available for gliclazide and Obesity
| Article | Year |
|---|---|
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin | 2020 |
Metformin Increases Cortisol Regeneration by 11βHSD1 in Obese Men With and Without Type 2 Diabetes Mellitus.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Comorbidity; Cross-Over Studies; Diabetes Mellitus, Typ | 2016 |
Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated | 2004 |
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe | 2005 |
[A new therapeutic approach to diabetes. Long-term survey].
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Retinopathy; Drug | 1977 |
[Survey of 832 case records of diabetes of adult onset treated by Diamicron. Evolution of metabolism and weight].
Topics: Adult; Aged; Biguanides; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Fe | 1978 |
Gliclazide (diamicron) in metabolic and vascular treatment of diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus; Female; Gliclazide; Humans; Male; Obesity; Sulfonylurea Compounds | 1977 |
13 other studies available for gliclazide and Obesity
| Article | Year |
|---|---|
Is Gliclazide Associated with a Lower Obesity-Related Cancer Risk Compared to Other Sulfonylureas? A Long-term Prospective Cohort Study.
Topics: Cohort Studies; Female; Gliclazide; Humans; Hypoglycemic Agents; Incidence; Male; Neoplasms; Obesity | 2020 |
Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats.
Topics: Animals; ATP-Binding Cassette Transporters; Cell Size; Gene Expression Regulation; Gliclazide; Heart | 2012 |
Development of novel gastroretentive floating particulate drug delivery system of gliclazide.
Topics: Alginates; Animals; Blood Glucose; Calcium Carbonate; Drug Carriers; Gastrointestinal Tract; Gelatin | 2012 |
Diabetes mellitus and weight control: differences of respiratory quotient in type 2 diabetic obese subjects receiving sulfonylureas and non-diabetic obese controls.
Topics: Calorimetry, Indirect; Carbon Dioxide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclaz | 2003 |
Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.
Topics: Acetylglucosaminidase; Administration, Oral; Adult; Aged; Creatinine; Diabetes Mellitus, Type 2; Fem | 2003 |
Lymphocyte ecto-5'-nucleotidase in obese type 2 diabetic patients treated with gliclazide.
Topics: 5'-Nucleotidase; Adenosine; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabet | 2006 |
Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus; Gliclazide; Humans; Hypoglycemic Agents; Insuli | 1980 |
Gliclazide in the treatment of obese NIDDM patients.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Human | 1994 |
Gliclazide in the treatment of obese non-insulin dependent diabetic patients.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans | 1993 |
Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection.
Topics: Amputation, Surgical; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 1998 |
Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combinati | 2000 |
Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazid | 1991 |
Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Erythrocytes; Female; Gliclazide; | 1985 |